Donor KIR genotype impacts on clinical outcome after T-cell depleted HLA matched related allogeneic transplantation for high-risk pediatric leukemia patients.

Allogeneic hematopoietic stem cell transplantation (HSCT) has a major role in the treatment of high-risk and relapse acute myeloid leukemia (AML) and high-risk acute lymphoblastic leukemia (ALL), the most important causes of death in children with cancer. [1,2] The best overall and relapse-free survivals of this procedure were observed in matched related donors (MRDs), only possible in less than one-third of patients. [3 –5] Recent reports revealed that even with a human leukocyte antigen (HLA) match, 20%–40% of patients develop graft-versus-host disease (GvHD).

Source: Biology of Blood and Marrow Transplantation - August 23, 2018 Category: Hematology Authors: Adela Escudero, Isabel Mart ínez Romera, Lucía Fernández, Jaime Valentín, Marta González-Vicent, José Luis Vicario, Rosario Madero Jarabo, Miguel Ángel Diaz, Antonio Pérez-Martínez Source Type: research